

# Enno Schmidt

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2972813/publications.pdf>

Version: 2024-02-01

347  
papers

15,729  
citations

16411

64  
h-index

31759

101  
g-index

407  
all docs

407  
docs citations

407  
times ranked

6299  
citing authors

#	ARTICLE	IF	CITATIONS
1	Pemphigoid diseases. <i>Lancet, The</i> , 2013, 381, 320-332.	6.3	896
2	Mechanisms of Autoantibody-Induced Pathology. <i>Frontiers in Immunology</i> , 2017, 8, 603.	2.2	377
3	Pemphigus. <i>Lancet, The</i> , 2019, 394, 882-894.	6.3	312
4	Serum Levels of Autoantibodies to BP180 Correlate With Disease Activity in Patients With Bullous Pemphigoid. <i>Archives of Dermatology</i> , 2000, 136, 174-8.	1.7	308
5	Definitions and outcome measures for bullous pemphigoid: Recommendations by an international panel of experts. <i>Journal of the American Academy of Dermatology</i> , 2012, 66, 479-485.	0.6	294
6	The registry of the German Network for Systemic Scleroderma: frequency of disease subsets and patterns of organ involvement. <i>Rheumatology</i> , 2008, 47, 1185-1192.	0.9	252
7	Diagnosis and management of pemphigus: Recommendations of an international panel of experts. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 575-585.e1.	0.6	224
8	Rituximab in autoimmune bullous diseases: mixed responses and adverse effects. <i>British Journal of Dermatology</i> , 2007, 156, 352-356.	1.4	176
9	Modern diagnosis of autoimmune blistering skin diseases. <i>Autoimmunity Reviews</i> , 2010, 10, 84-89.	2.5	175
10	Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID). <i>Arthritis Research and Therapy</i> , 2011, 13, R75.	1.6	170
11	Autoantibodies to Bullous Pemphigoid Antigen 180 Induce Dermalâ€“Epidermal Separation in Cryosections of Human Skin. <i>Journal of Investigative Dermatology</i> , 2002, 118, 664-671.	0.3	168
12	Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial. <i>Lancet, The</i> , 2017, 389, 1630-1638.	6.3	167
13	Prospektive Untersuchung der Inzidenz blasenbildender Autoimmundermatosen in Unterfranken. <i>JDDG - Journal of the German Society of Dermatology</i> , 2009, 7, 434-440.	0.4	166
14	Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV). <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 1900-1913.	1.3	159
15	Autoimmune Subepidermal Bullous Diseases of the Skin and Mucosae: Clinical Features, Diagnosis, and Management. <i>Clinical Reviews in Allergy and Immunology</i> , 2018, 54, 26-51.	2.9	158
16	Prospective analysis of the incidence of autoimmune bullous disorders in Lower Franconia, Germany. <i>JDDG - Journal of the German Society of Dermatology</i> , 2009, 7, 434-439.	0.4	154
17	Prevalence and Age Distribution of Pemphigus and Pemphigoid Diseases in Germany. <i>Journal of Investigative Dermatology</i> , 2016, 136, 2495-2498.	0.3	147
18	Enzymeâ€“linked immunosorbent assay using multimers of the 16th nonâ€“collagenous domain of the BP180 antigen for sensitive and specific detection of pemphigoid autoantibodies. <i>Experimental Dermatology</i> , 2007, 16, 770-777.	1.4	145

#	ARTICLE	IF	CITATIONS
19	Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseases. JDDG - Journal of the German Society of Dermatology, 2008, 6, 366-373.	0.4	144
20	Cicatrical pemphigoid: IgA and IgG autoantibodies target epitopes on both intra- and extracellular domains of bullous pemphigoid antigen 180. British Journal of Dermatology, 2001, 145, 778-783.	1.4	130
21	Rituximab for treatment-refractory pemphigus and pemphigoid: A case series of 17 patients. Journal of the American Academy of Dermatology, 2011, 65, 552-558.	0.6	130
22	Rituximab in refractory autoimmune bullous diseases. Clinical and Experimental Dermatology, 2006, 31, 503-508.	0.6	129
23	Autoantibodies in Lichen Planus Pemphigoides React with a Novel Epitope within the C-Terminal NC16A Domain of BP180. Journal of Investigative Dermatology, 1999, 113, 117-121.	0.3	127
24	Novel ELISA systems for antibodies to desmoglein 1 and 3: correlation of disease activity with serum autoantibody levels in individual pemphigus patients. Experimental Dermatology, 2010, 19, 458-463.	1.4	127
25	Correlation of Serum Levels of IgE Autoantibodies Against BP180 With Bullous Pemphigoid Disease Activity. JAMA Dermatology, 2017, 153, 30.	2.0	119
26	Mechanisms Causing Loss of Keratinocyte Cohesion in Pemphigus. Journal of Investigative Dermatology, 2018, 138, 32-37.	0.3	113
27	Autoantibodies to BP180 Associated with Bullous Pemphigoid Release Interleukin-6 and Interleukin-8 from Cultured Human Keratinocytes. Journal of Investigative Dermatology, 2000, 115, 842-848.	0.3	112
28	IgG4 and IgE are the major immunoglobulins targeting the NC 16A domain of BP 180 in bullous pemphigoid: Serum levels of these immunoglobulins reflect disease activity. Journal of the American Academy of Dermatology, 2000, 42, 577-583.	0.6	112
29	Desmocollin 3-mediated Binding Is Crucial for Keratinocyte Cohesion and Is Impaired in Pemphigus. Journal of Biological Chemistry, 2009, 284, 30556-30564.	1.6	108
30	Serological diagnosis of autoimmune bullous skin diseases: Prospective comparison of the BIOCHIP mosaic-based indirect immunofluorescence technique with the conventional multi-step single test strategy. Orphanet Journal of Rare Diseases, 2012, 7, 49.	1.2	106
31	Autoantibodies in a Subgroup of Patients with Linear IgA Disease React with the NC16A Domain of BP180. Journal of Investigative Dermatology, 1999, 113, 947-953.	0.3	105
32	Protein A immunoadsorption: a novel and effective adjuvant treatment of severe pemphigus. British Journal of Dermatology, 2003, 148, 1222-1229.	1.4	105
33	Development of ELISA for the specific determination of autoantibodies against envoplakin and periplakin in paraneoplastic pemphigus. Clinica Chimica Acta, 2009, 410, 13-18.	0.5	105
34	IgG4 and IgE are the major immunoglobulins targeting the NC16A domain of BP180 in Bullous pemphigoid: serum levels of these immunoglobulins reflect disease activity. Journal of the American Academy of Dermatology, 2000, 42, 577-83.	0.6	104
35	Pemphigoid diseases: Pathogenesis, diagnosis, and treatment. Autoimmunity, 2012, 45, 55-70.	1.2	102
36	Rituximab in Severe Pemphigus. Annals of the New York Academy of Sciences, 2009, 1173, 683-691.	1.8	100

#	ARTICLE	IF	CITATIONS
37	Clinical Features and Practical Diagnosis of Bullous Pemphigoid. <i>Dermatologic Clinics</i> , 2011, 29, 427-438.	1.0	99
38	Anti-p200 pemphigoid. <i>Journal of the American Academy of Dermatology</i> , 2014, 71, 185-191.	0.6	99
39	Population-Specific Association between a Polymorphic Variant in ST18, Encoding a Pro-Apoptotic Molecule, and Pemphigus Vulgaris. <i>Journal of Investigative Dermatology</i> , 2012, 132, 1798-1805.	0.3	98
40	Diagnosis of Autoimmune Blistering Diseases. <i>Frontiers in Medicine</i> , 2018, 5, 296.	1.2	97
41	Sensitive and specific assays for routine serological diagnosis of epidermolysis bullosa acquisita. <i>Journal of the American Academy of Dermatology</i> , 2013, 68, e89-e95.	0.6	95
42	Epidermolysis Bullosa Acquisita: From Pathophysiology to Novel Therapeutic Options. <i>Journal of Investigative Dermatology</i> , 2016, 136, 24-33.	0.3	94
43	Immunogenicity of rituximab in patients with severe pemphigus. <i>Clinical Immunology</i> , 2009, 132, 334-341.	1.4	90
44	Development of NC1 and NC2 domains of Type VII collagen ELISA for the diagnosis and analysis of the time course of epidermolysis bullosa acquisita patients. <i>Journal of Dermatological Science</i> , 2011, 62, 169-175.	1.0	90
45	Genetic identification and functional validation of Fc $\gamma$ RIV as key molecule in autoantibody-induced tissue injury. <i>Journal of Pathology</i> , 2012, 228, 8-19.	2.1	89
46	European Guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology – Part II. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 1926-1948.	1.3	86
47	Detection of elevated levels of IL-4, IL-6, and IL-10 in blister fluid of bullous pemphigoid. <i>Archives of Dermatological Research</i> , 1996, 288, 353-357.	1.1	85
48	IL-17A is functionally relevant and a potential therapeutic target in bullous pemphigoid. <i>Journal of Autoimmunity</i> , 2019, 96, 104-112.	3.0	85
49	Malignancies in Pemphigus and Pemphigoid Diseases. <i>Journal of Investigative Dermatology</i> , 2015, 135, 1445-1447.	0.3	84
50	Successful Adjuvant Treatment of Recalcitrant Epidermolysis Bullosa Acquisita With Anti-CD20 Antibody Rituximab. <i>Archives of Dermatology</i> , 2006, 142, 147-50.	1.7	82
51	Peptide-mediated desmoglein 3 crosslinking prevents pemphigus vulgaris autoantibody-induced skin blistering. <i>Journal of Clinical Investigation</i> , 2013, 123, 800-11.	3.9	82
52	Structural proteins of the dermal-epidermal junction targeted by autoantibodies in pemphigoid diseases. <i>Experimental Dermatology</i> , 2017, 26, 1154-1162.	1.4	79
53	The Diagnosis and Treatment of Autoimmune Blistering Skin Diseases. <i>Deutsches A&amp;#x0308;rztblatt International</i> , 2011, 108, 399-405, I-III.	0.6	79
54	Development of a simple enzyme-linked immunosorbent assay for the detection of autoantibodies in anti-p200 pemphigoid. <i>British Journal of Dermatology</i> , 2011, 164, 76-82.	1.4	77

#	ARTICLE	IF	CITATIONS
55	Epitope mapping of BP230 leading to a novel enzyme-linked immunosorbent assay for autoantibodies in bullous pemphigoid. <i>British Journal of Dermatology</i> , 2012, 166, 964-970.	1.4	77
56	Regulatory T-cell deficiency leads to pathogenic bullous pemphigoid antigen 230 autoantibody and autoimmune bullous disease. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 142, 1831-1842.e7.	1.5	77
57	Rituximab in Treatment-Resistant Autoimmune Blistering Skin Disorders. <i>Clinical Reviews in Allergy and Immunology</i> , 2008, 34, 56-64.	2.9	76
58	S2k guidelines for the treatment of pemphigus vulgaris/foiaceus and bullous pemphigoid. <i>JDDG - Journal of the German Society of Dermatology</i> , 2015, 13, 833-844.	0.4	76
59	Current therapy of the pemphigus group. <i>Clinics in Dermatology</i> , 2012, 30, 84-94.	0.8	74
60	Long-standing remission of recalcitrant juvenile pemphigus vulgaris after adjuvant therapy with rituximab. <i>British Journal of Dermatology</i> , 2005, 153, 449-451.	1.4	73
61	The Leukotriene B4 and its Receptor BLT1 Act as Critical Drivers of Neutrophil Recruitment in Murine Bullous Pemphigoid-Like Epidermolysis Bullosa Acquisita. <i>Journal of Investigative Dermatology</i> , 2017, 137, 1104-1113.	0.3	73
62	Antiepiligrin Cicatricial Pemphigoid. <i>Archives of Dermatology</i> , 1999, 135, 1091-8.	1.7	72
63	Immunoabsorption in dermatology. <i>Archives of Dermatological Research</i> , 2010, 302, 241-253.	1.1	72
64	European guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology – Part I. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 1750-1764.	1.3	72
65	S2k guideline for the diagnosis of pemphigus vulgaris/foiaceus and bullous pemphigoid. <i>JDDG - Journal of the German Society of Dermatology</i> , 2015, 13, 713-727.	0.4	69
66	Heat-shock protein 90 inhibition in autoimmunity to type VII collagen: evidence that nonmalignant plasma cells are not therapeutic targets. <i>Blood</i> , 2011, 117, 6135-6142.	0.6	68
67	Treatment of severe pemphigus with a combination of immunoabsorption, rituximab, pulsed dexamethasone and azathioprine/mycophenolate mofetil: a pilot study of 23 patients. <i>British Journal of Dermatology</i> , 2012, 166, 154-160.	1.4	68
68	Calculation of cutoff values based on the Autoimmune Bullous Skin Disorder Intensity Score ( ) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 2 for defining moderate, significant and extensive types of pemphigus. <i>British Journal of Dermatology</i> , 2016, 175, 142-149.	1.4	68
69	Clinical features and diagnosis of epidermolysis bullosa acquisita. <i>Expert Review of Clinical Immunology</i> , 2017, 13, 157-169.	1.3	68
70	Recommendations for the use of immunoapheresis in the treatment of autoimmune bullous diseases. <i>JDDG - Journal of the German Society of Dermatology</i> , 2007, 5, 881-887.	0.4	67
71	Klinisches und immunpathologisches Spektrum des paraneoplastischen Pemphigus. <i>JDDG - Journal of the German Society of Dermatology</i> , 2010, 8, 598-606.	0.4	67
72	IgG1 and IgG3 are the Major Immunoglobulin Subclasses Targeting Epitopes within the NC16A Domain of BP180 in Pemphigoid Gestationis. <i>Journal of Investigative Dermatology</i> , 1999, 113, 140-142.	0.3	66

#	ARTICLE	IF	CITATIONS
73	Repetitive Immunization Breaks Tolerance to Type XVII Collagen and Leads to Bullous Pemphigoid in Mice. <i>Journal of Immunology</i> , 2011, 187, 1176-1183.	0.4	66
74	Fc $\gamma$ 3 Receptors III and IV Mediate Tissue Destruction in a Novel Adult Mouse Model of Bullous Pemphigoid. <i>American Journal of Pathology</i> , 2014, 184, 2185-2196.	1.9	66
75	Genome-wide association study identifies new susceptibility loci for cutaneous lupus erythematosus. <i>Experimental Dermatology</i> , 2015, 24, 510-515.	1.4	66
76	IgE-mediated mechanisms in bullous pemphigoid and other autoimmune bullous diseases. <i>Expert Review of Clinical Immunology</i> , 2016, 12, 267-277.	1.3	64
77	BP180-specific IgG is associated with skin adverse events, therapy response, and overall survival in non-small cell lung cancer patients treated with checkpoint inhibitors. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 854-861.	0.6	64
78	IgG4 and IgE are the major immunoglobulins targeting the NC16A domain of BP180 in bullous pemphigoid: Serum levels of these immunoglobulins reflect disease activity. <i>Journal of the American Academy of Dermatology</i> , 2000, 42, 577-583.	0.6	63
79	Generation of Antibodies of Distinct Subclasses and Specificity Is Linked to H2s in an Active Mouse Model of Epidermolysis Bullosa Acquisita. <i>Journal of Investigative Dermatology</i> , 2011, 131, 167-176.	0.3	63
80	Monopathogenic vs multipathogenic explanations of pemphigus pathophysiology. <i>Experimental Dermatology</i> , 2016, 25, 839-846.	1.4	63
81	International Bullous Diseases Group: consensus on diagnostic criteria for epidermolysis bullosa acquisita. <i>British Journal of Dermatology</i> , 2018, 179, 30-41.	1.4	62
82	An open, multicentre, randomized clinical study in patients with bullous pemphigoid comparing methylprednisolone and azathioprine with methylprednisolone and dapsone. <i>British Journal of Dermatology</i> , 2017, 177, 1299-1305.	1.4	61
83	Diagnosis of autoimmune bullous diseases. <i>JDDG - Journal of the German Society of Dermatology</i> , 2018, 16, 1077-1091.	0.4	61
84	Updated S2K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV). <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 1689-1704.	1.3	61
85	The IL-8 release from cultured human keratinocytes, mediated by antibodies to bullous pemphigoid autoantigen 180, is inhibited by dapsone. <i>Clinical and Experimental Immunology</i> , 2001, 124, 157-162.	1.1	59
86	Apoptosis in pemphigus. <i>Autoimmunity Reviews</i> , 2009, 8, 533-537.	2.5	57
87	Bullous pemphigoid in infants: characteristics, diagnosis and treatment. <i>Orphanet Journal of Rare Diseases</i> , 2014, 9, 185.	1.2	57
88	Different signaling patterns contribute to loss of keratinocyte cohesion dependent on autoantibody profile in pemphigus. <i>Scientific Reports</i> , 2017, 7, 3579.	1.6	57
89	The Extent of Desmoglein 3 Depletion in Pemphigus Vulgaris Is Dependent on Ca <sup>2+</sup> -Induced Differentiation. <i>American Journal of Pathology</i> , 2011, 179, 1905-1916.	1.9	56
90	Immunoabsorption in Dermatology. <i>Therapeutic Apheresis and Dialysis</i> , 2012, 16, 311-320.	0.4	55

#	ARTICLE	IF	CITATIONS
91	Large International Validation of ABSIS and PDAI Pemphigus Severity Scores. <i>Journal of Investigative Dermatology</i> , 2019, 139, 31-37.	0.3	55
92	SARS-CoV-2 Transmission from Presymptomatic Meeting Attendee, Germany. <i>Emerging Infectious Diseases</i> , 2020, 26, 1935-1937.	2.0	55
93	Improved protocol for treatment of pemphigus vulgaris with protein A immunoabsorption. <i>Clinical and Experimental Dermatology</i> , 2006, 31, 768-774.	0.6	54
94	Current Treatment of Autoimmune Blistering Diseases. <i>Current Drug Discovery Technologies</i> , 2009, 6, 270-280.	0.6	54
95	Enzymatic autoantibody glycan hydrolysis alleviates autoimmunity against type VII collagen. <i>Journal of Autoimmunity</i> , 2012, 39, 304-314.	3.0	54
96	S2-Leitlinie zur Diagnostik des Pemphigus vulgaris/foliaceus und des bullösen Pemphigoids. <i>JDDG - Journal of the German Society of Dermatology</i> , 2015, 13, 713-727.	0.4	54
97	Laboratory Diagnosis and Clinical Profile of Anti-p200 Pemphigoid. <i>JAMA Dermatology</i> , 2016, 152, 897.	2.0	54
98	A sensitive and specific assay for the serological diagnosis of antilaminin 332 mucous membrane pemphigoid. <i>British Journal of Dermatology</i> , 2019, 180, 149-156.	1.4	53
99	Expert recommendations for the management of autoimmune bullous diseases during the COVID-19 pandemic. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e302-e303.	1.3	53
100	Neurological and psychiatric associations in bullous pemphigoid – more than skin deep?. <i>Experimental Dermatology</i> , 2017, 26, 1228-1234.	1.4	52
101	Clinical and immunopathological spectrum of paraneoplastic pemphigus. <i>JDDG - Journal of the German Society of Dermatology</i> , 2010, 8, 598-605.	0.4	51
102	Regulatory T Cells Suppress Inflammation and Blistering in Pemphigoid Diseases. <i>Frontiers in Immunology</i> , 2017, 8, 1628.	2.2	51
103	Epidemiology of Pemphigus. <i>JID Innovations</i> , 2021, 1, 100004.	1.2	51
104	Unmet Medical Needs in Chronic, Non-communicable Inflammatory Skin Diseases. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	51
105	Improvement of treatment-refractory atopic dermatitis by immunoabsorption: A pilot study. <i>Journal of Allergy and Clinical Immunology</i> , 2011, 127, 267-270.e6.	1.5	50
106	Serration pattern analysis for differentiating epidermolysis bullosa acquisita from other pemphigoid diseases. <i>Journal of the American Academy of Dermatology</i> , 2018, 78, 754-759.e6.	0.6	50
107	Sun-induced Life-threatening Lupus Nephritis. <i>Annals of the New York Academy of Sciences</i> , 2007, 1108, 35-40.	1.8	49
108	Apoptosis is not required for acantholysis in pemphigus vulgaris. <i>American Journal of Physiology - Cell Physiology</i> , 2009, 296, C162-C172.	2.1	49

#	ARTICLE	IF	CITATIONS
109	Serum levels of anti- $\alpha$ 7 type VII collagen antibodies detected by enzyme-linked immunosorbent assay in patients with epidermolysis bullosa acquisita are correlated with the severity of skin lesions. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013, 27, e224-30.	1.3	49
110	Recombinant IL-6 treatment protects mice from organ specific autoimmune disease by IL-6 classical signalling-dependent IL-1ra induction. <i>Journal of Autoimmunity</i> , 2013, 40, 74-85.	3.0	48
111	Emerging treatments for pemphigoid diseases. <i>Trends in Molecular Medicine</i> , 2013, 19, 501-512.	3.5	48
112	Methylprednisolone Blocks Autoantibody-Induced Tissue Damage in Experimental Models of Bullous Pemphigoid and Epidermolysis Bullosa Acquisita through Inhibition of Neutrophil Activation. <i>Journal of Investigative Dermatology</i> , 2013, 133, 2390-2399.	0.3	47
113	Prevalence of pemphigus and pemphigoid autoantibodies in the general population. <i>Orphanet Journal of Rare Diseases</i> , 2015, 10, 63.	1.2	46
114	Prospective studies on the routine use of a novel multivariant enzyme-linked immunosorbent assay for the diagnosis of autoimmune bullous diseases. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 889-894.e5.	0.6	46
115	Tissue Destruction in Bullous Pemphigoid Can Be Complement Independent and May Be Mitigated by C5aR2. <i>Frontiers in Immunology</i> , 2018, 9, 488.	2.2	46
116	Caspase-1 Independent IL-1 Release Mediates Blister Formation in Autoantibody-Induced Tissue Injury through Modulation of Endothelial Adhesion Molecules. <i>Journal of Immunology</i> , 2015, 194, 3656-3663.	0.4	44
117	Experimental Laminin 332 Mucous Membrane Pemphigoid Critically Involves C5aR1 and Reflects Clinical and Immunopathological Characteristics of the Human Disease. <i>Journal of Investigative Dermatology</i> , 2017, 137, 1709-1718.	0.3	44
118	Pathogenicity of Autoantibodies in Anti-p200 Pemphigoid. <i>PLoS ONE</i> , 2012, 7, e41769.	1.1	44
119	Childhood epidermolysis bullosa acquisita: a novel variant with reactivity to all three structural domains of type VII collagen. <i>British Journal of Dermatology</i> , 2002, 147, 592-597.	1.4	43
120	Autoimmune subepidermal blistering diseases in Uganda: correlation of autoantibody class with age of patients. <i>International Journal of Dermatology</i> , 2006, 45, 1047-1052.	0.5	43
121	Dual inhibition of complement factor 5 and leukotriene B4 synergistically suppresses murine pemphigoid disease. <i>JCI Insight</i> , 2019, 4, .	2.3	43
122	Treatment of pemphigus vulgaris and foliaceus with efgartigimod, a neonatal Fc receptor inhibitor: a phase II multicentre, open-label feasibility trial*. <i>British Journal of Dermatology</i> , 2022, 186, 429-439.	1.4	43
123	Elevated levels of interleukin-8 in blister fluid of bullous pemphigoid compared with suction blisters of healthy control subjects. <i>Journal of the American Academy of Dermatology</i> , 1996, 34, 310-312.	0.6	42
124	Successful pregnancy outcome under prolonged ustekinumab treatment in a patient with Crohn's disease and paradoxical psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, e191-e192.	1.3	42
125	Profibrotic Phenotype of Conjunctival Fibroblasts from Mucous Membrane Pemphigoid. <i>American Journal of Pathology</i> , 2011, 178, 187-197.	1.9	41
126	Clinical Features and Practical Diagnosis of Bullous Pemphigoid. <i>Immunology and Allergy Clinics of North America</i> , 2012, 32, 217-232.	0.7	41



#	ARTICLE	IF	CITATIONS
127	Efficacy and safety of rituximab in pemphigus: experience of the German Registry of Autoimmune Diseases. <i>JDDG - Journal of the German Society of Dermatology</i> , 2012, 10, 727-731.	0.4	41
128	Reduced Skin Blistering in Experimental Epidermolysis Bullosa Acquisita After Anti-TNF Treatment. <i>Molecular Medicine</i> , 2016, 22, 918-926.	1.9	41
129	Aberrant Expression and Secretion of Heat Shock Protein 90 in Patients with Bullous Pemphigoid. <i>PLoS ONE</i> , 2013, 8, e70496.	1.1	40
130	Rituximab as first-line treatment of pemphigus. <i>Lancet, The</i> , 2017, 389, 1956-1958.	6.3	40
131	Autoimmune and inherited subepidermal blistering diseases: advances in the clinic and the laboratory. <i>Advances in Dermatology</i> , 2000, 16, 113-57; discussion 158.	2.0	40
132	Histopathology of anti-laminin 5 mucous membrane pemphigoid. <i>Journal of the American Academy of Dermatology</i> , 2009, 61, 433-440.	0.6	39
133	Protective Endogenous Cyclic Adenosine 5â€²-Monophosphate Signaling Triggered by Pemphigus Autoantibodies. <i>Journal of Immunology</i> , 2010, 185, 6831-6838.	0.4	38
134	Routine detection of serum antidesmocollin autoantibodies is only useful in patients with atypical pemphigus. <i>Experimental Dermatology</i> , 2017, 26, 1267-1270.	1.4	38
135	The Anti-C1s Antibody TNT003 Prevents Complement Activation in the Skin Induced by Bullous Pemphigoid Autoantibodies. <i>Journal of Investigative Dermatology</i> , 2018, 138, 458-461.	0.3	38
136	GM-CSF Modulates Autoantibody Production and Skin Blistering in Experimental Epidermolysis Bullosa Acquisita. <i>Journal of Immunology</i> , 2014, 192, 559-571.	0.4	37
137	Clinical and immunological features and outcome of anti-p200 pemphigoid. <i>British Journal of Dermatology</i> , 2016, 175, 776-781.	1.4	37
138	Peptides Targeting the Desmoglein 3 Adhesive Interface Prevent Autoantibody-induced Acantholysis in Pemphigus. <i>Journal of Biological Chemistry</i> , 2009, 284, 8589-8595.	1.6	36
139	Pemphigus Vulgaris IgG Cause Loss of Desmoglein-Mediated Adhesion and Keratinocyte Dissociation Independent of Epidermal Growth Factor Receptor. <i>American Journal of Pathology</i> , 2009, 174, 475-485.	1.9	36
140	Animal models for autoimmune bullous dermatoses. <i>Experimental Dermatology</i> , 2010, 19, 2-11.	1.4	36
141	Mucous membrane pemphigoid. <i>Autoimmunity Reviews</i> , 2022, 21, 103036.	2.5	36
142	Subacute prurigo variant of bullous pemphigoid: Autoantibodies show the same specificity compared with classic bullous pemphigoid. <i>Journal of the American Academy of Dermatology</i> , 2002, 47, 133-136.	0.6	35
143	Identification of Quantitative Trait Loci in Experimental Epidermolysis Bullosa Acquisita. <i>Journal of Investigative Dermatology</i> , 2012, 132, 1409-1415.	0.3	35
144	Meeting Report of the Pathogenesis of Pemphigus and Pemphigoid Meeting in Munich, September 2016. <i>Journal of Investigative Dermatology</i> , 2017, 137, 1199-1203.	0.3	34

#	ARTICLE	IF	CITATIONS
145	Incidence of pemphigoid diseases in Northern Germany in 2016 – first data from the Schleswig-Holstein Registry of Autoimmune Bullous Diseases. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 1197-1202.	1.3	34
146	S2k guidelines (consensus statement) for diagnosis and therapy of dermatitis herpetiformis initiated by the European Academy of Dermatology and Venereology (EADV). <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 1251-1277.	1.3	34
147	Successful Treatment of Mucous Membrane Pemphigoid with the Anti-CD-20 Antibody Rituximab. <i>Acta Dermato-Venereologica</i> , 2009, 89, 101-102.	0.6	33
148	Safety and Clinical Outcomes of Rituximab Treatment in Patients with Multiple Sclerosis and Neuromyelitis Optica: Experience from a National Online Registry (GRAID). <i>Journal of Neuroimmune Pharmacology</i> , 2016, 11, 1-8.	2.1	33
149	Linear IgA Disease: Successful Application of Immunoabsorption and Review of the Literature. <i>Dermatology</i> , 2010, 220, 259-263.	0.9	32
150	Co-occurrence of autoantibodies in healthy blood donors. <i>Experimental Dermatology</i> , 2014, 23, 519-521.	1.4	32
151	Allelic and copy-number variations of Fc $\gamma$ R3 affect granulocyte function and susceptibility for autoimmune blistering diseases. <i>Journal of Autoimmunity</i> , 2015, 61, 36-44.	3.0	32
152	Detection of IL-1 $\alpha$ , IL-1 $\beta$ and IL-1 receptor antagonist in blister fluid of bullous pemphigoid. <i>Journal of Dermatological Science</i> , 1996, 11, 142-147.	1.0	31
153	Antibodies to desmogleins 1 and 3, but not to BP180, induce blisters in human skin grafted onto SCID mice. <i>Journal of Pathology</i> , 2001, 193, 117-124.	2.1	31
154	Prospective study in bullous pemphigoid: association of high serum anti-BP180 IgG levels with increased mortality and reduced Karnofsky score. <i>British Journal of Dermatology</i> , 2018, 179, 918-924.	1.4	31
155	Whole-Genome Expression Profiling in Skin Reveals SYK As a Key Regulator of Inflammation in Experimental Epidermolysis Bullosa Acquisita. <i>Frontiers in Immunology</i> , 2018, 9, 249.	2.2	31
156	A successful treatment with ustekinumab in a case of antilaminin-31 pemphigoid associated with psoriasis. <i>British Journal of Dermatology</i> , 2013, 168, 1367-1369.	1.4	30
157	EGFR inhibitors erlotinib and lapatinib ameliorate epidermal blistering in pemphigus vulgaris in a non-linear, V-shaped relationship. <i>Experimental Dermatology</i> , 2014, 23, 33-38.	1.4	30
158	COVID-19 and implications for dermatological and allergological diseases. <i>JDDG - Journal of the German Society of Dermatology</i> , 2020, 18, 815-824.	0.4	30
159	Analysis of serum markers of cellular immune activation in patients with bullous pemphigoid. <i>Experimental Dermatology</i> , 2017, 26, 1248-1252.	1.4	29
160	Resolution in bullous pemphigoid. <i>Seminars in Immunopathology</i> , 2019, 41, 645-654.	2.8	29
161	Anti-p200 pemphigoid is the most common pemphigoid disease with serum antibodies against the dermal side by indirect immunofluorescence microscopy on human salt-split skin. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 1195-1197.	0.6	29
162	Covid-19 pandemic and the skin. <i>International Journal of Dermatology</i> , 2020, 59, 1312-1319.	0.5	29

#	ARTICLE	IF	CITATIONS
163	Cytokines in autoimmune bullous skin diseases. Epiphenomena or contribution to pathogenesis?. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2009, 144, 339-49.	0.8	29
164	A distinct cutaneous microbiota profile in autoimmune bullous disease patients. <i>Experimental Dermatology</i> , 2017, 26, 1221-1227.	1.4	28
165	Targeting IgE Antibodies by Immunoabsorption in Atopic Dermatitis. <i>Frontiers in Immunology</i> , 2018, 9, 254.	2.2	28
166	Multicenter prospective study on multivariant diagnostics of autoimmune bullous dermatoses using the BIOCHIP technology. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1315-1322.	0.6	28
167	Updated international expert recommendations for the management of autoimmune bullous diseases during the COVID-19 pandemic. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e412-e414.	1.3	28
168	Specific immunoabsorption of pathogenic autoantibodies in pemphigus requires the entire ectodomains of desmogleins. <i>Experimental Dermatology</i> , 2014, 23, 253-259.	1.4	26
169	Atypical Clinical and Serological Manifestation of Pemphigus Vegetans: A Case Report and Review of the Literature. <i>Case Reports in Dermatology</i> , 2017, 9, 121-130.	0.3	26
170	A new <i>ex vivo</i> human oral mucosa model reveals that p38 MAPK inhibition is not effective in preventing autoantibody-induced mucosal blistering in pemphigus. <i>British Journal of Dermatology</i> , 2020, 182, 987-994.	1.4	26
171	Diagnosis and Treatment of Patients with Autoimmune Bullous Disorders in Germany. <i>Dermatologic Clinics</i> , 2011, 29, 663-671.	1.0	25
172	IgE-Specific Immunoabsorption for Treatment of Recalcitrant Atopic Dermatitis. <i>JAMA Dermatology</i> , 2014, 150, 1350.	2.0	25
173	Cicatricial pemphigoid differs from bullous pemphigoid and pemphigoid gestationis regarding the fine specificity of autoantibodies to the BP180 NC16A domain. <i>Journal of Dermatological Science</i> , 2002, 28, 68-75.	1.0	24
174	Elevated expression and release of tissue-type, but not urokinase-type, plasminogen activator after binding of autoantibodies to bullous pemphigoid antigen 180 in cultured human keratinocytes. <i>Clinical and Experimental Immunology</i> , 2004, 135, 497-504.	1.1	24
175	Forschen für die Praxis: Diagnostik subepidermal blasenbildender Autoimmundermatosen. <i>JDDG - Journal of the German Society of Dermatology</i> , 2009, 7, 296-300.	0.4	24
176	Generalized cowpox infection in a patient with Darier disease. <i>British Journal of Dermatology</i> , 2011, 164, 1116-1118.	1.4	24
177	Polymorphisms in the mitochondrially encoded ATP synthase 8 gene are associated with susceptibility to bullous pemphigoid in the German population. <i>Experimental Dermatology</i> , 2015, 24, 715-717.	1.4	24
178	Prevalence and age distribution of pemphigus and pemphigoid diseases among paediatric patients in Germany. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 2600-2605.	1.3	24
179	The retinoid-related orphan receptor alpha is essential for the end-stage effector phase of experimental epidermolysis bullosa acquisita. <i>Journal of Pathology</i> , 2015, 237, 111-122.	2.1	23
180	Autoantibodies to Multiple Epitopes on the Non-Collagenous-1 Domain of Type VII Collagen Induce Blisters. <i>Journal of Investigative Dermatology</i> , 2015, 135, 1565-1573.	0.3	23

#	ARTICLE	IF	CITATIONS
181	CD20-directed therapy in autoimmune diseases involving the skin: role of rituximab. <i>Expert Review of Dermatology</i> , 2008, 3, 259-278.	0.3	22
182	Relapse-associated autoantibodies to BP180 in a patient with anti-p200 pemphigoid. <i>Clinical and Experimental Dermatology</i> , 2010, 35, 614-617.	0.6	22
183	Clearance rates of circulating and tissue-bound autoantibodies to type VII collagen in experimental epidermolysis bullosa acquisita. <i>British Journal of Dermatology</i> , 2010, 162, 1064-1070.	1.4	22
184	Antibodies to the C-terminus of laminin $\beta$ 31 are present in a distinct subgroup of patients with systemic and cutaneous lupus erythematosus. <i>Lupus</i> , 2012, 21, 1482-1483.	0.8	22
185	Treatment of bullous pemphigoid with adjuvant immunoadsorption: A case series. <i>Journal of the American Academy of Dermatology</i> , 2014, 71, 1018-1020.	0.6	22
186	Diagnostic performance of the $\alpha$ MESACUP anti-Skin profile TEST. <i>European Journal of Dermatology</i> , 2016, 26, 56-63.	0.3	22
187	Evaluation of Site- and Autoantigen-Specific Characteristics of Mucous Membrane Pemphigoid. <i>JAMA Dermatology</i> , 2022, 158, 84.	2.0	22
188	Treatment of bullous pemphigoid with dapsone, methylprednisolone, and topical clobetasol propionate: a retrospective study of 62 cases. <i>Cutis</i> , 2005, 76, 205-9.	0.4	22
189	Scarring autoimmune bullous disease in a Ugandan patient with autoantibodies to BP180, BP230, and laminin 5. <i>Journal of the American Academy of Dermatology</i> , 2006, 54, S43-S46.	0.6	21
190	Transition from pemphigus foliaceus to bullous pemphigoid: Intermolecular B-cell epitope spreading without IgG subclass shifting. <i>Journal of the American Academy of Dermatology</i> , 2009, 61, 333-336.	0.6	21
191	Ca <sup>2+</sup> signalling is critical for autoantibody-induced blistering of human epidermis in pemphigus*. <i>British Journal of Dermatology</i> , 2021, 185, 595-604.	1.4	21
192	Bullous autoimmune dermatoses: clinical features, diagnostic evaluation, and treatment options. <i>Deutsches Ärzteblatt International</i> , 2021, 118, 413-420.	0.6	21
193	High Levels of Soluble CD23 in Blister Fluid of Patients With Bullous Pemphigoid. <i>Archives of Dermatology</i> , 1995, 131, 966.	1.7	20
194	Linear IgA disease with circulating IgA antibodies against the NC16A domain of BP180. <i>British Journal of Dermatology</i> , 1999, 140, 964-966.	1.4	20
195	Premonitory Epidermolysis Bullosa Acquisita Mimicking Eyelid Dermatitis. <i>American Journal of Clinical Dermatology</i> , 2010, 11, 1.	3.3	20
196	Calcitriol Treatment Ameliorates Inflammation and Blistering in Mouse Models of Epidermolysis Bullosa Acquisita. <i>Journal of Investigative Dermatology</i> , 2018, 138, 301-309.	0.3	20
197	Immunoadsorption of Desmoglein-3-Specific IgG Abolishes the Blister-Inducing Capacity of Pemphigus Vulgaris IgG in Neonatal Mice. <i>Frontiers in Immunology</i> , 2018, 9, 1935.	2.2	20
198	Identification of novel therapeutic targets for blocking acantholysis in pemphigus. <i>British Journal of Pharmacology</i> , 2020, 177, 5114-5130.	2.7	20

#	ARTICLE	IF	CITATIONS
199	S2k guidelines for the treatment of pemphigus vulgaris/foiaceus and bullous pemphigoid: 2019 update. JDDG - Journal of the German Society of Dermatology, 2020, 18, 516-526.	0.4	20
200	Treatment with anti-neonatal Fc receptor (FcRn) antibody ameliorates experimental epidermolysis bullosa acquisita in mice. British Journal of Pharmacology, 2020, 177, 2381-2392.	2.7	20
201	CD19+ B lymphocytes are the major source of human antibody-secreting hybridomas generated by electrofusion. Journal of Immunological Methods, 2001, 255, 93-102.	0.6	19
202	A Highly Sensitive and Simple Assay for the Detection of Circulating Autoantibodies against Full-Length Bullous Pemphigoid Antigen 180. Journal of Autoimmunity, 2002, 18, 299-309.	3.0	19
203	Glucocorticosteroid-resistant pemphigoid gestationis: Successful treatment with adjuvant immunoadsorption. Journal of Dermatology, 2012, 39, 168-171.	0.6	19
204	Serum autoantibodies against the dermal-epidermal junction in patients with chronic pruritic disorders, elderly individuals and blood donors prospectively recruited. British Journal of Dermatology, 2014, 170, 943-947.	1.4	19
205	Biological and Clinical Response to Omalizumab in a Patient with Bullous Pemphigoid. Acta Dermato-Venereologica, 2018, 98, 284-286.	0.6	19
206	Orf followed by erythema multiforme. Journal of the European Academy of Dermatology and Venereology, 2006, 20, 612-613.	1.3	17
207	The p.Arg435His Variation of IgG3 With High Affinity to FcRn Is Associated With Susceptibility for Pemphigus Vulgaris—Analysis of Four Different Ethnic Cohorts. Frontiers in Immunology, 2018, 9, 1788.	2.2	17
208	Milestones in Personalized Medicine in Pemphigus and Pemphigoid. Frontiers in Immunology, 2020, 11, 591971.	2.2	17
209	A randomised controlled trial to compare the safety, effectiveness and cost-effectiveness of doxycycline (200 mg/day) with that of oral prednisolone (0.5 mg/kg/day) for initial treatment of bullous pemphigoid: the Bullous Pemphigoid Steroids and Tetracyclines (BLISTER) trial. Health Technology Assessment, 2017, 21, 1-90.	1.3	17
210	A long-term study of a patient with anti-p200 pemphigoid: correlation of autoantibody levels with disease activity and an example of epitope spreading. British Journal of Dermatology, 2012, 167, 1179-1183.	1.4	16
211	Immunoadsorber for specific apheresis of autoantibodies in the treatment of bullous pemphigoid. Archives of Dermatological Research, 2016, 308, 31-38.	1.1	16
212	Parkinson disease and multiple sclerosis are not associated with autoantibodies against structural proteins of the dermal-epidermal junction. British Journal of Dermatology, 2016, 175, 407-409.	1.4	16
213	Genomewide association study identifies <i>GALC</i> as susceptibility gene for mucous membrane pemphigoid. Experimental Dermatology, 2017, 26, 1214-1220.	1.4	16
214	Diagnostik blasenbildender Autoimmundermatosen. JDDG - Journal of the German Society of Dermatology, 2018, 16, 1077-1092.	0.4	16
215	Adjuvant treatment of severe/refractory bullous pemphigoid with protein A immunoadsorption. JDDG - Journal of the German Society of Dermatology, 2018, 16, 1109-1118.	0.4	16
216	Serologic characterization of anti-p200 pemphigoid: Epitope spreading as a common phenomenon. Journal of the American Academy of Dermatology, 2021, 84, 1155-1157.	0.6	16

#	ARTICLE	IF	CITATIONS
217	Immunoglobulin M pemphigoid. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, 1486-1492.	0.6	16
218	Identification of two novel bullous pemphigoid- associated alleles, HLA-DQA1*05:05 and -DRB1*07:01, in Germans. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 228.	1.2	16
219	Dapsone Suppresses Disease in Preclinical Murine Models of Pemphigoid Diseases. <i>Journal of Investigative Dermatology</i> , 2021, 141, 2587-2595.e2.	0.3	16
220	Detection of elevated levels of IL-4, IL-6, and IL-10 in blister fluid of bullous pemphigoid. <i>Archives of Dermatological Research</i> , 1996, 288, 353-357.	1.1	16
221	Bullous Pemphigoid with Localized Umbilical Involvement. <i>Acta Dermato-Venereologica</i> , 2009, 89, 419-420.	0.6	15
222	Long-term outcomes of rituximab therapy in pemphigus. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 2884-2889.	1.3	15
223	Recent progresses and perspectives in autoimmune bullous diseases. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 145, 1145-1147.	1.5	15
224	The risk of COVID-19 in patients with bullous pemphigoid and pemphigus: A population-based cohort study. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, 79-87.	0.6	15
225	Serum Levels of Autoantibodies to Desmoglein 3 in Patients with Therapy-resistant Pemphigus Vulgaris Successfully Treated with Adjuvant Intravenous Immunoglobulins. <i>Acta Dermato-Venereologica</i> , 2003, 84, 48-52.	0.6	14
226	Mapping of B cell epitopes on desmoglein 3 in pemphigus vulgaris patients by the use of overlapping peptides. <i>Journal of Dermatological Science</i> , 2012, 65, 102-109.	1.0	14
227	Diagnostics of autoimmune bullous diseases in German dermatology departments. <i>JDDG - Journal of the German Society of Dermatology</i> , 2012, 10, 492-499.	0.4	14
228	Vitamin D status in patients with bullous pemphigoid. <i>British Journal of Dermatology</i> , 2013, 168, 873-874.	1.4	14
229	Value of BIOCHIP Technology in the Serological Diagnosis of Pemphigoid Gestationis. <i>Acta Dermato-Venereologica</i> , 2017, 97, 128-130.	0.6	14
230	Assessment of healthcare costs for patients with pemphigus and bullous pemphigoid in an academic centre in Germany. <i>British Journal of Dermatology</i> , 2020, 182, 1296-1297.	1.4	14
231	Omalizumab: an underutilized treatment option in bullous pemphigoid patients with comorbidities. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e469-e472.	1.3	14
232	The burden of neurological comorbidities in six autoimmune bullous diseases: a population-based study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 2074-2078.	1.3	14
233	Doxycycline compared with prednisolone therapy for patients with bullous pemphigoid: cost-effectiveness analysis of the BLISTER trial. <i>British Journal of Dermatology</i> , 2018, 178, 415-423.	1.4	13
234	Coexistence of bullous pemphigoid with neuropsychiatric comorbidities is associated with anti-β230 seropositivity. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 2067-2073.	1.3	13

#	ARTICLE	IF	CITATIONS
235	Epidemiology of Autoimmune Bullous Diseases. , 2015, , 251-263.		13
236	Research in practice: diagnosis of subepidermal autoimmune bullous disorders. JDDG - Journal of the German Society of Dermatology, 2009, 7, 296-300.	0.4	12
237	Eczematous Reaction to Intravenous Immunglobulin. JAMA Dermatology, 2014, 150, 1120.	2.0	12
238	Association with <sc>HLAâ€œDRB1</sc> in Egyptian and German pemphigus vulgaris patients. Tissue Antigens, 2015, 85, 283-286.	1.0	12
239	Complement Receptor 1 (CR1, CD35) Polymorphisms and Soluble CR1: A Proposed Anti-inflammatory Role to Quench the Fire of â€œFogo Selvagemâ€•Pemphigus Foliaceus. Frontiers in Immunology, 2019, 10, 2585.	2.2	12
240	More Severe Erosive Phenotype Despite Lower Circulating Autoantibody Levels in Dipeptidyl Peptidase-4 Inhibitor (DPP4i)-Associated Bullous Pemphigoid: A Retrospective Cohort Study. American Journal of Clinical Dermatology, 2021, 22, 117-127.	3.3	12
241	The impact of lesional inflammatory cellular infiltrate on the phenotype of bullous pemphigoid. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 1702-1711.	1.3	12
242	Evaluation and Comparison of Clinical and iLaboratory Characteristics of Patients With IgA Epidermolysis Bullosa Acquisita, Linear IgA Bullous Dermatitis, and IgG Epidermolysis Bullosa Acquisita. JAMA Dermatology, 2021, 157, 917.	2.0	12
243	Epidermolysis bullosa acquisita and anti-p200 pemphigoid as major subepidermal autoimmune bullous diseases diagnosed by floor binding on indirect immunofluorescence microscopy using human salt-split skin. Indian Journal of Dermatology, Venereology and Leprology, 2017, 83, 550.	0.2	12
244	Diagnostik blasenbildender Autoimmundermatosen an deutschen Hautkliniken. JDDG - Journal of the German Society of Dermatology, 2012, 10, 492-500.	0.4	11
245	Genetic variability of immuneâ€related lncRNAs: polymorphisms in <i>LINCâ€PINT</i> and <i>LY86â€AS1</i> are associated with pemphigus foliaceus susceptibility. Experimental Dermatology, 2021, 30, 831-840.	1.4	11
246	Comparison of Two Diagnostic Assays for Anti-Laminin 332 Mucous Membrane Pemphigoid. Frontiers in Immunology, 2021, 12, 773720.	2.2	11
247	IgE-Selective Immunoabsorption for Severe Atopic Dermatitis. Frontiers in Medicine, 2018, 5, 27.	1.2	10
248	Normal human skin is superior to monkey oesophagus substrate for detection of circulating <sc>BP</sc> 180â€•<sc>NC</sc> 16Aâ€specific IgG antibodies in bullous pemphigoid. British Journal of Dermatology, 2019, 180, 1099-1106.	1.4	10
249	Expression of PDâ€1 and Timâ€3 is increased in skin of patients with bullous pemphigoid and pemphigus vulgaris. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 486-492.	1.3	10
250	Prevalence and presumptive triggers of localized bullous pemphigoid. Journal of Dermatology, 2021, 48, 1257-1261.	0.6	10
251	Immunological features and factors associated with mucocutaneous bullous pemphigoid â€“ a retrospective cohort study. JDDG - Journal of the German Society of Dermatology, 2021, 19, 1289-1295.	0.4	10
252	Lupus erythematosus profundus in an 8-year-old child. Journal of the European Academy of Dermatology and Venereology, 2007, 21, 132-133.	1.3	9

#	ARTICLE	IF	CITATIONS
253	Paraneoplastic pemphigus with anti-BP180 autoantibodies and Castleman disease. <i>British Journal of Dermatology</i> , 2017, 176, 824-826.	1.4	9
254	Increased sensitivity and high specificity of indirect immunofluorescence in detecting IgG subclasses for diagnosis of bullous pemphigoid. <i>Clinical and Experimental Dermatology</i> , 2018, 43, 248-253.	0.6	9
255	Adjuvant treatment with secukinumab induced long term remission in a patient with severe bullous pemphigoid. <i>JDDG - Journal of the German Society of Dermatology</i> , 2020, 18, 1478-1480.	0.4	9
256	Diagnostic Value and Practicability of Serration Pattern Analysis by Direct Immunofluorescence Microscopy in Pemphigoid Diseases. <i>Acta Dermato-Venereologica</i> , 2021, 101, adv00410.	0.6	9
257	The Association of Bullous Pemphigoid With Atopic Dermatitis and Allergic Rhinitis—A Population-Based Study. <i>Dermatitis</i> , 2022, 33, 268-276.	0.8	9
258	Characterization of the skin microbiota in bullous pemphigoid patients and controls reveals novel microbial indicators of disease. <i>Journal of Advanced Research</i> , 2023, 44, 71-79.	4.4	9
259	Therapeutic effect of etanercept in anti-laminin 5 (laminin 332) mucous membrane pemphigoid. <i>International Journal of Dermatology</i> , 2011, 50, 1129-1131.	0.5	8
260	Automated direct immunofluorescence analyses of skin biopsies. <i>Journal of Cutaneous Pathology</i> , 2016, 43, 227-235.	0.7	8
261	Bullous pemphigoid autoantibody-mediated complement fixation is abolished by the low-molecular-weight heparin tinzaparin sodium. <i>British Journal of Dermatology</i> , 2019, 181, 593-594.	1.4	8
262	Patients with bullous pemphigoid and comorbid psoriasis present with less blisters and lower serum levels of anti-BP180 autoantibodies. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 981-987.	1.3	8
263	International multicentre observational study to assess the efficacy and safety of a 0.5 mg kg <sup>-1</sup> per day starting dose of oral corticosteroids to treat bullous pemphigoid. <i>British Journal of Dermatology</i> , 2021, , .	1.4	8
264	Genetic association and differential expression of HLA Complex Group lncRNAs in pemphigus. <i>Journal of Autoimmunity</i> , 2021, 123, 102705.	3.0	8
265	A Family with Atypical Hailey Hailey Disease- Is There More to the Underlying Genetics than ATP2C1?. <i>PLoS ONE</i> , 2015, 10, e0121253.	1.1	8
266	Clinical and Serological Characterization of Orf-Induced Immunobullous Disease. <i>JAMA Dermatology</i> , 2022, 158, 670.	2.0	8
267	HLA alleles in British Caucasians with mucous membrane pemphigoid. <i>Eye</i> , 2018, 32, 1540-1541.	1.1	7
268	Grover disease and bullous pemphigoid: a clinicopathological study of six cases. <i>Clinical and Experimental Dermatology</i> , 2019, 44, 524-527.	0.6	7
269	EndoS Reduces the Pathogenicity of Anti-mCOL7 IgG through Reduced Binding of Immune Complexes to Neutrophils. <i>PLoS ONE</i> , 2014, 9, e85317.	1.1	7
270	Presence of Cutaneous Complement Deposition Distinguishes between Immunological and Histological Features of Bullous Pemphigoid—Insights from a Retrospective Cohort Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 3928.	1.0	7



#	ARTICLE	IF	CITATIONS
271	C5aR2 Deficiency Ameliorates Inflammation in Murine Epidermolysis Bullosa Acquisita by Regulating Fc $\gamma$ 3 Receptor Expression on Neutrophils. <i>Journal of Investigative Dermatology</i> , 2022, 142, 2715-2723.e2.	0.3	7
272	Late-onset inversa recessive dystrophic epidermolysis bullosa caused by glycine substitutions in collagen type VII. <i>British Journal of Dermatology</i> , 2011, 164, 1104-1106.	1.4	6
273	Concomitant Bullous Pemphigoid and Dermatitis Herpetiformis. <i>Dermatology</i> , 2013, 226, 217-221.	0.9	6
274	Contemporary management of pemphigus. <i>Expert Opinion on Orphan Drugs</i> , 2013, 1, 295-314.	0.5	6
275	A refractory, cutaneous, subepidermal bullous disease. <i>Clinical and Experimental Dermatology</i> , 2016, 41, 573-575.	0.6	6
276	Immunfluoreszenztechniken. , 2016, , 37-49.		6
277	High levels of soluble CD23 in blister fluid of patients with bullous pemphigoid. <i>Archives of Dermatology</i> , 1995, 131, 966-7.	1.7	6
278	Acquired hyperplasia of the tunica dartos mimicking smooth muscle hamartoma. <i>Clinical and Experimental Dermatology</i> , 2007, 32, 588-589.	0.6	5
279	EffektivitÄt und Sicherheit von Rituximab beim Pemphigus: Ergebnisse aus dem Deutschen Register für Autoimmunerkrankungen. <i>JDDG - Journal of the German Society of Dermatology</i> , 2012, 10, 727-732.	0.4	5
280	A childhood subepidermal autoimmune bullous disease resembling mechanobullous epidermolysis bullosa acquisita. <i>British Journal of Dermatology</i> , 2015, 173, 871-874.	1.4	5
281	Chronic bullous disease of childhood with IgG reactivity to p200 antigen. <i>International Journal of Dermatology</i> , 2017, 56, 773-775.	0.5	5
282	Adjuvante Behandlung des schweren/refraktären bullösen Pemphigoids mit ProteinÄ-immunoadsorption. <i>JDDG - Journal of the German Society of Dermatology</i> , 2018, 16, 1109-1119.	0.4	5
283	Anti-laminin 332 mucous membrane pemphigoid with laryngeal involvement - adjuvant treatment with immunoadsorption and rituximab. <i>JDDG - Journal of the German Society of Dermatology</i> , 2018, 16, 897-900.	0.4	5
284	Overlap of Bullous, Anti-“Laminin-332, and Anti-p200 Pemphigoid With Concomitant Anti-“Contactin-1“Positive Inflammatory Polyneuropathy Treated With Intravenous Immunoglobulins as a Manifestation of Epitope Spreading. <i>JAMA Dermatology</i> , 2019, 155, 631.	2.0	5
285	Alterations of Total Serum Immunoglobulin Concentrations in Pemphigus and Pemphigoid: Selected IgG2 Deficiency in Bullous Pemphigoid. <i>Frontiers in Medicine</i> , 2020, 7, 472.	1.2	5
286	Pathogenic Activation and Therapeutic Blockage of Fc $\gamma$ 3-Expressing Polymorphonuclear Leukocytes in IgA Pemphigus. <i>Journal of Investigative Dermatology</i> , 2021, 141, 2820-2828.	0.3	5
287	Diagnosis and clinical severity markers of bullous pemphigoid. <i>F1000 Medicine Reports</i> , 2009, 1, .	2.9	5
288	Childhood epidermolysis bullosa acquisita: Confirmation of diagnosis by skin deficient in Type VII Collagen, enzyme-linked immunosorbent assay, and immunoblotting. <i>Indian Journal of Dermatology</i> , 2016, 61, 329.	0.1	5

#	ARTICLE	IF	CITATIONS
289	Localisation of bullous pemphigoid antigen 180 (BP180) in cultured human keratinocytes: functionally relevant modification by calcium. Archives of Dermatological Research, 2006, 298, 283-290.	1.1	4
290	Tibial bone keratoprosthesis: reversing blindness in mucous membrane pemphigoid. JDDG - Journal of the German Society of Dermatology, 2017, 15, 1024-1026.	0.4	4
291	Diagnostic Value of Linear Fluorescence Along the Basement Membrane of Sweat Gland Ducts in Bullous Pemphigoid. Acta Dermato-Venereologica, 2017, 97, 622-626.	0.6	4
292	Polymorphisms in the Mitochondrial Genome Are Associated With Bullous Pemphigoid in Germans. Frontiers in Immunology, 2019, 10, 2200.	2.2	4
293	Postherpetic epidermolysis bullosa acquisita. Journal of the European Academy of Dermatology and Venereology, 2019, 33, e118-e119.	1.3	4
294	Unsuspected Associations of Variants within the Genes NOTCH4 and STEAP2-AS1 Uncovered by a GWAS in Endemic Pemphigus Foliaceus. Journal of Investigative Dermatology, 2021, 141, 2741-2744.	0.3	4
295	Multiple modes of action mediate the therapeutic effect of IVIg in experimental epidermolysis bullosa acquisita. Journal of Investigative Dermatology, 2021, , .	0.3	4
296	Natural Occurrence of Autoantibodies against Basement Membrane Proteins in Epidermolysis Bullosa. Journal of Investigative Dermatology, 2022, 142, 2014-2019.e3.	0.3	4
297	Increased Fibrosis in a Mouse Model of Anti-Laminin 332 Mucous Membrane Pemphigoid Remains Unaltered by Inhibition of Aldehyde Dehydrogenase. Frontiers in Immunology, 2021, 12, 812627.	2.2	4
298	Genetic Associations and Differential mRNA Expression Levels of Host Genes Suggest a Viral Trigger for Endemic Pemphigus Foliaceus. Viruses, 2022, 14, 879.	1.5	4
299	The association of six autoimmune bullous diseases with thyroid disorders: A population-based study. Journal of the European Academy of Dermatology and Venereology, 0, , .	1.3	4
300	Serum autoantibody reactivity in bullous pemphigoid is associated with neuropsychiatric disorders and the use of antidiabetics and antipsychotics: a large, prospective cohort study. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 2181-2189.	1.3	4
301	Trehalose conserves expression of bullous pemphigoid antigen 180 during desiccation and freezing. Journal of Immunological Methods, 2003, 275, 179-190.	0.6	3
302	Treatment of severe pemphigus vulgaris of the scalp with adjuvant rituximab and immunoadsorption. European Journal of Dermatology, 2012, 22, 786-787.	0.3	3
303	S2k-Leitlinie zur Therapie des Pemphigus vulgaris/foliaceus und des bullösen Pemphigoid. JDDG - Journal of the German Society of Dermatology, 2015, 13, 833-845.	0.4	3
304	Myeloid-related proteins-8 and -14 are expressed but dispensable in the pathogenesis of experimental epidermolysis bullosa acquisita and bullous pemphigoid. Journal of Dermatological Science, 2016, 81, 165-172.	1.0	3
305	Bullous pemphigoid with linear lesions and antibodies exclusively against the soluble ectodomain of BP180 (LADÄ1). JDDG - Journal of the German Society of Dermatology, 2019, 17, 933-935.	0.4	3
306	Detection of u-serrated patterns in direct immunofluorescence images of autoimmune bullous diseases by inhibition-augmented COSFIRE filters. International Journal of Medical Informatics, 2019, 122, 27-36.	1.6	3

#	ARTICLE	IF	CITATIONS
307	Heavy Exposure of Children Aged 9–12 Years With Severe Acute Respiratory Syndrome Coronavirus 2 Did Not Lead to Infection. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2020, 9, 620-621.	0.6	3
308	Penile mucous membrane pemphigoid. <i>JDDG - Journal of the German Society of Dermatology</i> , 2020, 18, 727-729.	0.4	3
309	Low prevalence of late-onset neutropenia after rituximab treatment in patients with pemphigus. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1824-1825.	0.6	3
310	A Case of Anti-laminin $\gamma$ 1 Pemphigoid with Cutaneous Polyarteritis Nodosa. <i>Nishinihon Journal of Dermatology</i> , 2013, 75, 7-10.	0.0	3
311	High levels of soluble CD23 in blister fluid of patients with bullous pemphigoid. <i>Archives of Dermatology</i> , 1995, 131, 966-967.	1.7	3
312	Mast cell-deficient mice <i>Mcpt5Cre/Dicer</i> <sup>fl/fl</sup> redefine the role of mast cells in experimental bullous pemphigoid. <i>Skin Health and Disease</i> , 2022, 2, .	0.7	3
313	Anti-BP230 Only Bullous Pemphigoid Constitutes a Distinct Disease Subgroup with Characteristic Serological and Clinical Features. <i>Journal of Investigative Dermatology</i> , 2022, 142, 3110-3113.e8.	0.3	3
314	Longstanding Painful Hemorrhagic Vesicles and Erosions on the Lower Leg—Quiz Case. <i>Archives of Dermatology</i> , 2011, 147, 235.	1.7	2
315	Travel-associated infectious skin diseases. <i>JDDG - Journal of the German Society of Dermatology</i> , 2020, 18, 730-733.	0.4	2
316	Immunization with desmoglein 3 induces non-pathogenic autoantibodies in mice. <i>PLoS ONE</i> , 2021, 16, e0259586.	1.1	2
317	Coincidence of Bullous Pemphigoid and Pityriasis Rubra Pilaris. <i>Acta Dermato-Venereologica</i> , 2022, 102, adv00674.	0.6	2
318	How Do Experts Treat Patients with Bullous Pemphigoid around the World? An International Survey. <i>JID Innovations</i> , 2022, 2, 100129.	1.2	2
319	Increasing the diagnostic sensitivity for mucous membrane pemphigoid by detection of salivary autoantibodies. <i>British Journal of Dermatology</i> , 2016, 174, 956-957.	1.4	1
320	The BLISTER study: possible overestimation of tetracycline efficacy – Authors' reply. <i>Lancet</i> , The, 2017, 390, 735-736.	6.3	1
321	Anti-Laminin-332-Schleimhautpemphigoid mit laryngealer Beteiligung - adjuvante Behandlung mit Immunadsorption und Rituximab. <i>JDDG - Journal of the German Society of Dermatology</i> , 2018, 16, 897-900.	0.4	1
322	Epidermolysis bullosa acquisita: the most frequent pemphigoid disease in patients with dermal binding autoantibodies by indirect immunofluorescence microscopy on human salt-split skin in Tehran, Iran. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e370-e372.	1.3	1
323	Genetic and Environmental Risk Factors of Autoimmune Bullous Diseases. , 2015, , 131-139.		1
324	Pathogenic Autoantibody Derived from Regulatory T Cell-Deficient Scurfy Mice Targets Type VII Collagen and Leads to Epidermolysis Bullosa Acquisita-Like Blistering Disease. <i>Journal of Investigative Dermatology</i> , 2022, 142, 980-984.e4.	0.3	1

#	ARTICLE	IF	CITATIONS
325	Sustained CD19+CD27+ Memory B Cell Depletion after Rituximab Treatment in Patients with Pemphigus Vulgaris. Acta Dermato-Venereologica, 2022, 102, adv00679.	0.6	1
326	Quiz case of the month. European Radiology, 1999, 9, 573-574.	2.3	0
327	Schleimhautpemphigoid mit Autoantikörpern gegen Laminin 5. JDDG - Journal of the German Society of Dermatology, 2006, 4, no.	0.4	0
328	Empfehlungen für die Anwendung der Immunapherese bei der Therapie bullöser Autoimmundermatosen. JDDG - Journal of the German Society of Dermatology, 2007, 5, ---.	0.4	0
329	Empfehlungen für den Einsatz von Rituximab (anti-CD20-Antikörper) bei bullösen Autoimmundermatosen. JDDG - Journal of the German Society of Dermatology, 2008, 6, ---.	0.4	0
330	Case of subepidermal blistering disease with autoantibodies to both laminin 31 and laminin 33. Journal of Dermatology, 2013, 40, 491-492.	0.6	0
331	AB0734...Prevalence and co-occurrence of autoantibodies in blood donors. Annals of the Rheumatic Diseases, 2013, 71, 680.11-680.	0.5	0
332	Pemphigus Vegetans. , 2015, , 701-705.		0
333	A rare bullous variant of dermatitis herpetiformis. British Journal of Dermatology, 2016, 174, 231-233.	1.4	0
334	Wiederherstellung der Sehfähigkeit beim Schleimhautpemphigoid durch Keratoprothese aus dem Tibiaknochen. JDDG - Journal of the German Society of Dermatology, 2017, 15, 1024-1026.	0.4	0
335	Anti-Desmoglein 1 IgG/IgA pemphigus associated with thymoma. JDDG - Journal of the German Society of Dermatology, 2017, 15, 1147-1148.	0.4	0
336	Anti-Desmoglein 1 IgG/IgA-Pemphigus in Verbindung mit einem Thymom. JDDG - Journal of the German Society of Dermatology, 2017, 15, 1147-1149.	0.4	0
337	Koexistenz eines mukokutanen Pemphigus vulgaris mit einem später hinzugetretenen bullösen Pemphigoid. JDDG - Journal of the German Society of Dermatology, 2021, 19, 40-43.	0.4	0
338	Immunologische Merkmale und Faktoren im Zusammenhang mit dem mukokutanen bullösen Pemphigoid - eine retrospektive Kohortenstudie. JDDG - Journal of the German Society of Dermatology, 2021, 19, 1289-1296.	0.4	0
339	Meilensteine der personalisierten Medizin bei Pemphigus und Pemphigoid. Karger Kompass Autoimmun, 0, , 1-8.	0.0	0
340	Neue diagnostische und therapeutische Methoden. Fortschritte Der Praktischen Dermatologie Und Venerologie, 2013, , 473-482.	0.0	0
341	Life-Threatening Pemphigus Vulgaris. , 2015, , 35-43.		0
342	Single Step Multivariant Analysis of Serum Autoantibodies in Autoimmune Blistering Diseases Using BIOCHIP® Mosaic Technology. , 2015, , 153-160.		0

#	ARTICLE	IF	CITATIONS
343	Pemphigus Foliaceus and Pemphigus Erythematosus. , 2015, , 691-700.		0
344	Immunfluoreszenztechniken. , 2015, , 1-20.		0
345	Anti-p200 Pemphigoid. , 2021, , 235-239.		0
346	A teenager with blisters and crusts. JDDG - Journal of the German Society of Dermatology, 2022, 20, 533-536.	0.4	0
347	Distinct metabolite profile in pemphigus vulgaris. Journal of Investigative Dermatology, 2022, , .	0.3	0